• Mahshid Sadat Mirmoezzi Medical Student at the Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
  • Mohammad Shurideh Yazdi Department of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran
  • Omid Gholami Department of Physiology and Pharmacology, Faculty of Medicine, Sabzevar University of Medical Sciences, Sabzevar, Iran



Fluticasone Propionate, Mometaseone Furoate, Allergic Rhinitis, Total Nasal Symptom Score (TNSS) questionnaire


Objective: Allergic rhinitis is the most prevalent of allergic diseases in the world. Nasal corticosteroids are the most applicable drugs for the treatment of allergic rhinitis. In this study, we compared the efficacy of fluticasone propionate (FP) and mometasone furoate (MF) nasal sprays in the treatment of allergic rhinitis based on total nasal symptom score (TNSS) questionnaire.

Methods: For this study, 75 allergic rhinitis patients based on skin prick test and inclusion criteria were randomly assigned to two groups: FP and MF groups. FP group received 200 µg dose of FP nasal spray (1 spray/nostril) daily and the MF group received 100 mg dose of MF nasal spray (1 spray/nostril) daily for 8 w. The effects of the two agents were compared based on TNSS questionnaire in 0, 4 and 8 w after the beginning of the treatment.

Results: Results showed that patients in both groups exhibited significant improvement in their TNSS (P Value<0.001). A detailed TNSS analysis showed MF to be more effective for relieving all symptoms than FP. The most difference is in decreasing postnasal discharge (PND) symptom. However, the difference for relieving all symptoms is not significant (P value>0.05).

Conclusion: In conclusion, FP and MF are significantly effective in relieving of allergic rhinitis symptoms. Even though, the difference between the two is not significant for 8 w therapy. 


Download data is not yet available.


Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76.

Mak KK, Ku MS, Lu KH, Sun HL, Lue KH. Comparison of mometasone furoate monohydrate (Nasonex) and fluticasone propionate (Flixonase) nasal sprays in the treatment of dust mite-sensitive children with perennial allergic rhinitis. Pediatr Neonatol 2013;54:239-45.

Craig TJ, Ferguson BJ, Krouse JH. Sleep impairment in allergic rhinitis, rhinosinusitis, and nasal polyposis. Am J Otolaryngol 2008;29:209-17.

Giavina-Bianchi P, Agondi R, Stelmach R, Cukier A, Kalil J. Fluticasone furoate nasal spray in the treatment of allergic rhinitis. Ther Clin Risk Manag 2008;4:465-72.

Hochhaus G. Pharmacokinetic/pharmacodynamic profile of mometasone furoate nasal spray: potential effects on clinical safety and efficacy. Clin Ther 2008;30:1-13.

Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001;23:1339-54.

Caliskaner Z, Naiboglu B, Kutlu A, Kartal O, Ozturk S, Onem Y, et al. Risk factors for oral allergy syndrome in patients with seasonal allergic rhinitis. Med Oral Patol Oral Cir Bucal 2011;16:312-6.

Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 study group. Ann Allergy Asthma Immunol 1997;79:237-45.

Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-y treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol 2009;73:651-7.

Costa DJ, Amouyal M, Lambert P, Ryan D, Schunemann HJ, Daures JP, et al. How representative are clinical study patients with allergic rhinitis in primary care? J Allergy Clin Immunol 2011;127:920-6.

Nathan RA, Berger W, Yang W, Cheema A, Silvey M, Wu W, et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:497-505.

Fokkens WJ, Jogi R, Reinartz S, Sidorenko I, Sitkauskiene B, van Oene C, et al. Once-daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007;62:1078-84.

Scadding GK, Lund VJ, Jacques LA, Richards DH. A placebo-controlled study of fluticasone propionate aqueous nasal spray and beclomethasone dipropionate in perennial rhinitis: efficacy in allergic and non-allergic perennial rhinitis. Clin Exp Allergy 1995;25:737-43.

Ford LB, Matz J, Hankinson T, Prillaman B, Georges G. A comparison of fluticasone propionate nasal spray and cetirizine in ragweed fall seasonal allergic rhinitis. Allergy Asthma Proc 2015;36:313-9.

Okubo K, Okamasa A, Honma G, Komatsubara M. Efficacy and safety of fluticasone furoate nasal spray in Japanese children with perennial allergic rhinitis: a multicentre, randomized, double-blind, placebo-controlled trial. Allergy Asthma Proc 2014;63:543-51.

Yonezaki M, Akiyama K, Karaki M, Goto R, Inamoto R, Samukawa Y, et al. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis. Auris Nasus Larynx 2016;43:292-7.

Chandra S, Huliraj N, Giriyanna Gowda, Gangaboraiah, Parasuramalu Bg. Randomized, open lable, active-controlled study to assess and compare health-related quality of life with mometasone and formotrol versus fluticasone and formotrol dry powder inhaler in mild to moderate persistent Asthma. Asian J Pharm Clin Res 2015;8:296-8.



How to Cite

Mirmoezzi, M. S., M. S. Yazdi, and O. Gholami. “COMPARATIVE STUDY ON THE EFFICACY OF MOMETASONE AND FLUTICASONE NASAL SPRAYS FOR TREATMENT OF ALLERGIC RHINITIS”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 9, no. 3, Mar. 2017, pp. 211-4, doi:10.22159/ijpps.2017v9i3.15958.



Original Article(s)